Retrograde Cricopharyngeus Dysfunction effectively treated with low dose botulinum toxin. A case report from Italy.
R-CPD
Retrograde Cricopharyngeus Dysfunction (R-CPD)
abelchia
botulinum injection
case report
cricopharyngeus muscle
inability to burp
onabotulinum toxin-A
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
06
2023
accepted:
25
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
A large constellation of hitherto unexplained symptoms including inability to burp, gurgling noises from the chest and lower neck, abdominal bloating, flatulence, painful hiccups and emetophobia was defined as Retrograde Cricopharyngeus Dysfunction (R-CPD) in 2019. First choice treatment of R-CPD involves injection of botulinum toxin into the cricopharyngeus muscle under local or general anesthesia. This treatment has been found to be effective in the vast majority of subjects, with limited adverse events and prolonged therapeutic effects. Notwithstanding, R-CPD is still a poorly understood and underestimated disease, and a specific therapeutic dosage range of botulinum toxin (BT) has not been yet established. In this report, we describe the first case of R-CPD diagnosed in Italy, successfully treated with unilateral, anesthesia-free injection of 10 units of onabotulinum toxin into the cricopharyngeus muscle, representing the lowest dose reported to date.
Identifiants
pubmed: 37621856
doi: 10.3389/fneur.2023.1238304
pmc: PMC10444988
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1238304Informations de copyright
Copyright © 2023 Pavesi, Balzano, Mauramati, Giudice, Fresia, Todisco, Alfonsi and Cosentino.
Déclaration de conflit d'intérêts
The authors declare that the research were conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ear Nose Throat J. 2023 Mar 2;:1455613231162203
pubmed: 36864723
Qual Life Res. 1996 Oct;5(5):469-80
pubmed: 8973126
Intern Med. 2019 Apr 1;58(7):929-931
pubmed: 30449811
J Gastroenterol Hepatol. 2001 Mar;16(3):349-51
pubmed: 11339431
OTO Open. 2021 Feb 02;5(1):2473974X21989587
pubmed: 33598599
Am J Otolaryngol. 2005 May-Jun;26(3):157-62
pubmed: 15858769
Eur Arch Otorhinolaryngol. 2021 Dec;278(12):5087-5091
pubmed: 33893849
Neurogastroenterol Motil. 2022 May;34(5):e14250
pubmed: 34435723
Ann Otol Rhinol Laryngol. 2013 Feb;122(2):100-8
pubmed: 23534124
Dysphagia. 2023 Apr;38(2):543-557
pubmed: 34313849
Laryngoscope. 2023 Jul 8;:
pubmed: 37421251
Gastroenterology. 1987 Oct;93(4):818-22
pubmed: 3623025
Gastroenterology. 1989 Jan;96(1):274-5
pubmed: 2909435
OTO Open. 2020 Jun 29;4(2):2473974X20938342
pubmed: 32647778
Front Pharmacol. 2017 Feb 22;8:80
pubmed: 28275351
Ann Otol Rhinol Laryngol. 1994 Jan;103(1):31-5
pubmed: 8291857
Front Neurol. 2022 Dec 21;13:1005655
pubmed: 36619911
OTO Open. 2019 Mar 15;3(1):2473974X19834553
pubmed: 31236539